ID   RPB1_HUMAN              Reviewed;        1970 AA.
AC   P24928; A6NN93; B9EH88; Q6NX41;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2009, sequence version 2.
DT   10-MAY-2017, entry version 191.
DE   RecName: Full=DNA-directed RNA polymerase II subunit RPB1;
DE            Short=RNA polymerase II subunit B1;
DE            EC=2.7.7.6;
DE   AltName: Full=DNA-directed RNA polymerase II subunit A;
DE   AltName: Full=DNA-directed RNA polymerase III largest subunit;
DE   AltName: Full=RNA-directed RNA polymerase II subunit RPB1;
DE            EC=2.7.7.48;
GN   Name=POLR2A; Synonyms=POLR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1542581; DOI=10.1093/nar/20.4.910;
RA   Wintzerith M., Acker J., Vicaire S., Vigneron M., Kedinger C.;
RT   "Complete sequence of the human RNA polymerase II largest subunit.";
RL   Nucleic Acids Res. 20:910-910(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7622068; DOI=10.1016/0378-1119(95)00081-G;
RA   Mita K., Tsuji H., Morimyo M., Takahashi E., Nenoi M., Ichimura S.,
RA   Yamauchi M., Hongo E., Hayashi A.;
RT   "The human gene encoding the largest subunit of RNA polymerase II.";
RL   Gene 159:285-286(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION, IDENTIFICATION IN THE RNA POLYMERASE II CORE-COMPLEX, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9852112; DOI=10.1074/jbc.273.51.34444;
RA   Kershnar E., Wu S.-Y., Chiang C.-M.;
RT   "Immunoaffinity purification and functional characterization of human
RT   transcription factor IIH and RNA polymerase II from clonal cell lines
RT   that conditionally express epitope-tagged subunits of the multiprotein
RT   complexes.";
RL   J. Biol. Chem. 273:34444-34453(1998).
RN   [7]
RP   INTERACTION WITH SAFB.
RX   PubMed=9671816; DOI=10.1093/nar/26.15.3542;
RA   Nayler O., Straetling W., Bourquin J.-P., Stagljar I., Lindemann L.,
RA   Jasper H., Hartmann A.M., Fackelmeyer F.O., Ullrich A., Stamm S.;
RT   "SAF-B couples transcription and pre-mRNA splicing to SAR/MAR
RT   elements.";
RL   Nucleic Acids Res. 26:3542-3549(1998).
RN   [8]
RP   IDENTIFICATION IN A COMPLEX WITH HTATSF1; CCNT1; NCL; SUPT5H AND CDK9.
RX   PubMed=10393184; DOI=10.1093/emboj/18.13.3688;
RA   Parada C.A., Roeder R.G.;
RT   "A novel RNA polymerase II-containing complex potentiates Tat-enhanced
RT   HIV-1 transcription.";
RL   EMBO J. 18:3688-3701(1999).
RN   [9]
RP   INTERACTION WITH HTATSF1.
RX   PubMed=10454543; DOI=10.1128/MCB.19.9.5960;
RA   Kim J.B., Yamaguchi Y., Wada T., Handa H., Sharp P.A.;
RT   "Tat-SF1 protein associates with RAP30 and human SPT5 proteins.";
RL   Mol. Cell. Biol. 19:5960-5968(1999).
RN   [10]
RP   INTERACTION WITH FNBP3.
RX   PubMed=12381297; DOI=10.1016/S0022-2836(02)00968-3;
RA   Allen M., Friedler A., Schon O., Bycroft M.;
RT   "The structure of an FF domain from human HYPA/FBP11.";
RL   J. Mol. Biol. 323:411-416(2002).
RN   [11]
RP   INTERACTION WITH SYNCRIP.
RX   PubMed=12376575; DOI=10.1074/mcp.M200029-MCP200;
RA   Carty S.M., Greenleaf A.L.;
RT   "Hyperphosphorylated C-terminal repeat domain-associating proteins in
RT   the nuclear proteome link transcription to DNA/chromatin modification
RT   and RNA processing.";
RL   Mol. Cell. Proteomics 1:598-610(2002).
RN   [12]
RP   INTERACTION WITH DDX5.
RX   PubMed=12527917; DOI=10.1038/sj.onc.1206067;
RA   Rossow K.L., Janknecht R.;
RT   "Synergism between p68 RNA helicase and the transcriptional
RT   coactivators CBP and p300.";
RL   Oncogene 22:151-156(2003).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites
RT   from human T cells using immobilized metal affinity chromatography and
RT   tandem mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [14]
RP   INTERACTION WITH CCNT2.
RX   PubMed=15563843; DOI=10.1016/j.gene.2004.08.027;
RA   Kurosu T., Zhang F., Peterlin B.M.;
RT   "Transcriptional activity and substrate recognition of cyclin T2 from
RT   P-TEFb.";
RL   Gene 343:173-179(2004).
RN   [15]
RP   INTERACTION WITH CCNL2.
RX   PubMed=14684736; DOI=10.1074/jbc.M312895200;
RA   Yang L., Li N., Wang C., Yu Y., Yuan L., Zhang M., Cao X.;
RT   "Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved
RT   in pre-mRNA splicing and induces apoptosis of human hepatocellular
RT   carcinoma cells.";
RL   J. Biol. Chem. 279:11639-11648(2004).
RN   [16]
RP   INTERACTION WITH MEN1.
RX   PubMed=14992727; DOI=10.1016/S1097-2765(04)00081-4;
RA   Hughes C.M., Rozenblatt-Rosen O., Milne T.A., Copeland T.D.,
RA   Levine S.S., Lee J.C., Hayes D.N., Shanmugam K.S., Bhattacharjee A.,
RA   Biondi C.A., Kay G.F., Hayward N.K., Hess J.L., Meyerson M.;
RT   "Menin associates with a trithorax family histone methyltransferase
RT   complex and with the hoxc8 locus.";
RL   Mol. Cell 13:587-597(2004).
RN   [17]
RP   INTERACTION WITH SFRS19.
RX   PubMed=15992770; DOI=10.1016/j.bbrc.2005.06.053;
RA   Katsarou M.E., Papakyriakou A., Katsaros N., Scorilas A.;
RT   "Expression of the C-terminal domain of novel human SR-A1 protein:
RT   interaction with the CTD domain of RNA polymerase II.";
RL   Biochem. Biophys. Res. Commun. 334:61-68(2005).
RN   [18]
RP   INTERACTION WITH SETD2.
RX   PubMed=16118227; DOI=10.1074/jbc.M504012200;
RA   Sun X.-J., Wei J., Wu X.-Y., Hu M., Wang L., Wang H.-H., Zhang Q.-H.,
RA   Chen S.-J., Huang Q.-H., Chen Z.;
RT   "Identification and characterization of a novel human histone H3
RT   lysine 36 specific methyltransferase.";
RL   J. Biol. Chem. 280:35261-35271(2005).
RN   [19]
RP   INTERACTION WITH SETD2.
RX   PubMed=16314571; DOI=10.1073/pnas.0506350102;
RA   Li M., Phatnani H.P., Guan Z., Sage H., Greenleaf A.L., Zhou P.;
RT   "Solution structure of the Set2-Rpb1 interacting domain of human Set2
RT   and its interaction with the hyperphosphorylated C-terminal domain of
RT   Rpb1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17636-17641(2005).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1909 AND TYR-1923, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [21]
RP   INTERACTION WITH PAF1 IN PAF1/RNA POLYMERASE II.
RC   TISSUE=Fetal pancreas;
RX   PubMed=16491129; DOI=10.1038/sj.onc.1209353;
RA   Moniaux N., Nemos C., Schmied B.M., Chauhan S.C., Deb S., Morikane K.,
RA   Choudhury A., Vanlith M., Sutherlin M., Sikela J.M.,
RA   Hollingsworth M.A., Batra S.K.;
RT   "The human homologue of the RNA polymerase II-associated factor 1
RT   (hPaf1), localized on the 19q13 amplicon, is associated with
RT   tumorigenesis.";
RL   Oncogene 25:3247-3257(2006).
RN   [22]
RP   INTERACTION WITH SUPT6H, AND PHOSPHORYLATION.
RX   PubMed=17234882; DOI=10.1101/gad.1503107;
RA   Yoh S.M., Cho H., Pickle L., Evans R.M., Jones K.A.;
RT   "The Spt6 SH2 domain binds Ser2-P RNAPII to direct Iws1-dependent mRNA
RT   splicing and export.";
RL   Genes Dev. 21:160-174(2007).
RN   [23]
RP   INTERACTION WITH CMTR1.
RX   PubMed=18533109; DOI=10.1016/j.bbrc.2008.05.137;
RA   Haline-Vaz T., Silva T.C.L., Zanchin N.I.T.;
RT   "The human interferon-regulated ISG95 protein interacts with RNA
RT   polymerase II and shows methyltransferase activity.";
RL   Biochem. Biophys. Res. Commun. 372:719-724(2008).
RN   [24]
RP   INTERACTION WITH SCAF8.
RX   PubMed=18550522; DOI=10.1074/jbc.M803540200;
RA   Becker R., Loll B., Meinhart A.;
RT   "Snapshots of the RNA processing factor SCAF8 bound to different
RT   phosphorylated forms of the carboxyl-terminal domain of RNA polymerase
RT   II.";
RL   J. Biol. Chem. 283:22659-22669(2008).
RN   [25]
RP   FUNCTION AS RNA-DIRECTED RNA POLYMERASE.
RX   PubMed=18032511; DOI=10.1128/JVI.01758-07;
RA   Chang J., Nie X., Chang H.E., Han Z., Taylor J.;
RT   "Transcription of hepatitis delta virus RNA by RNA polymerase II.";
RL   J. Virol. 82:1118-1127(2008).
RN   [26]
RP   INTERACTION WITH SETD1A; SETD1B AND WDR82.
RX   PubMed=17998332; DOI=10.1128/MCB.01356-07;
RA   Lee J.H., Skalnik D.G.;
RT   "Wdr82 is a C-terminal domain-binding protein that recruits the Setd1A
RT   Histone H3-Lys4 methyltransferase complex to transcription start sites
RT   of transcribed human genes.";
RL   Mol. Cell. Biol. 28:609-618(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1849; TYR-1874;
RP   SER-1896; TYR-1909; SER-1913; SER-1920; TYR-1923; SER-1927 AND
RP   SER-1934, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [28]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [29]
RP   INTERACTION WITH ATF7IP.
RX   PubMed=19106100; DOI=10.1074/jbc.M807098200;
RA   Liu L., Ishihara K., Ichimura T., Fujita N., Hino S., Tomita S.,
RA   Watanabe S., Saitoh N., Ito T., Nakao M.;
RT   "MCAF1/AM is involved in Sp1-mediated maintenance of cancer-associated
RT   telomerase activity.";
RL   J. Biol. Chem. 284:5165-5174(2009).
RN   [30]
RP   PHOSPHORYLATION BY CDK7.
RX   PubMed=19450536; DOI=10.1016/j.molcel.2009.04.016;
RA   Akhtar M.S., Heidemann M., Tietjen J.R., Zhang D.W., Chapman R.D.,
RA   Eick D., Ansari A.Z.;
RT   "TFIIH kinase places bivalent marks on the carboxy-terminal domain of
RT   RNA polymerase II.";
RL   Mol. Cell 34:387-393(2009).
RN   [31]
RP   PHOSPHORYLATION BY CDK7 AND CDK9.
RX   PubMed=19667075; DOI=10.1128/MCB.00637-09;
RA   Glover-Cutter K., Larochelle S., Erickson B., Zhang C., Shokat K.,
RA   Fisher R.P., Bentley D.L.;
RT   "TFIIH-associated Cdk7 kinase functions in phosphorylation of C-
RT   terminal domain Ser7 residues, promoter-proximal pausing, and
RT   termination by RNA polymerase II.";
RL   Mol. Cell. Biol. 29:5455-5464(2009).
RN   [32]
RP   PHOSPHORYLATION BY CDK7.
RX   PubMed=19136461; DOI=10.1093/nar/gkn1061;
RA   Lolli G.;
RT   "Binding to DNA of the RNA-polymerase II C-terminal domain allows
RT   discrimination between Cdk7 and Cdk9 phosphorylation.";
RL   Nucleic Acids Res. 37:1260-1268(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1843; THR-1854;
RP   SER-1878; SER-1882; SER-1899; SER-1913; SER-1917; SER-1920; SER-1927;
RP   SER-1931 AND SER-1934, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [34]
RP   INTERACTION WITH RECQL5, AND FUNCTION.
RX   PubMed=20231364; DOI=10.1128/MCB.01583-09;
RA   Islam M.N., Fox D. III, Guo R., Enomoto T., Wang W.;
RT   "RecQL5 promotes genome stabilization through two parallel
RT   mechanisms--interacting with RNA polymerase II and acting as a
RT   helicase.";
RL   Mol. Cell. Biol. 30:2460-2472(2010).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   INTERACTION WITH U2AF2.
RX   PubMed=21536736; DOI=10.1101/gad.2038011;
RA   David C.J., Boyne A.R., Millhouse S.R., Manley J.L.;
RT   "The RNA polymerase II C-terminal domain promotes splicing activation
RT   through recruitment of a U2AF65-Prp19 complex.";
RL   Genes Dev. 25:972-983(2011).
RN   [38]
RP   PHOSPHORYLATION BY CDK9.
RX   PubMed=21127351; DOI=10.1074/jbc.M110.176628;
RA   Cojocaru M., Bouchard A., Cloutier P., Cooper J.J., Varzavand K.,
RA   Price D.H., Coulombe B.;
RT   "Transcription factor IIS cooperates with the E3 ligase UBR5 to
RT   ubiquitinate the CDK9 subunit of the positive transcription elongation
RT   factor B.";
RL   J. Biol. Chem. 286:5012-5022(2011).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1917 AND SER-1931, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [40]
RP   METHYLATION AT ARG-1810 BY CARM1, AND MUTAGENESIS OF ARG-1810.
RX   PubMed=21454787; DOI=10.1126/science.1202663;
RA   Sims R.J. III, Rojas L.A., Beck D., Bonasio R., Schuller R.,
RA   Drury W.J. III, Eick D., Reinberg D.;
RT   "The C-terminal domain of RNA polymerase II is modified by site-
RT   specific methylation.";
RL   Science 332:99-103(2011).
RN   [41]
RP   PHOSPHORYLATION, AND DOMAIN.
RX   PubMed=22137580; DOI=10.1016/j.molcel.2011.11.006;
RA   Egloff S., Zaborowska J., Laitem C., Kiss T., Murphy S.;
RT   "Ser7 phosphorylation of the CTD recruits the RPAP2 Ser5 phosphatase
RT   to snRNA genes.";
RL   Mol. Cell 45:111-122(2012).
RN   [42]
RP   UBIQUITINATION.
RX   PubMed=22466610; DOI=10.1038/ng.2229;
RA   Nakazawa Y., Sasaki K., Mitsutake N., Matsuse M., Shimada M.,
RA   Nardo T., Takahashi Y., Ohyama K., Ito K., Mishima H., Nomura M.,
RA   Kinoshita A., Ono S., Takenaka K., Masuyama R., Kudo T., Slor H.,
RA   Utani A., Tateishi S., Yamashita S., Stefanini M., Lehmann A.R.,
RA   Yoshiura K.I., Ogi T.;
RT   "Mutations in UVSSA cause UV-sensitive syndrome and impair RNA
RT   polymerase IIo processing in transcription-coupled nucleotide-excision
RT   repair.";
RL   Nat. Genet. 44:586-592(2012).
RN   [43]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 PROTEIN ICP22 (MICROBIAL
RP   INFECTION).
RX   PubMed=23029222; DOI=10.1371/journal.pone.0045749;
RA   Guo L., Wu W.J., Liu L.D., Wang L.C., Zhang Y., Wu L.Q., Guan Y.,
RA   Li Q.H.;
RT   "Herpes simplex virus 1 ICP22 inhibits the transcription of viral gene
RT   promoters by binding to and blocking the recruitment of P-TEFb.";
RL   PLoS ONE 7:E45749-E45749(2012).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-27; SER-217; SER-1850;
RP   SER-1864; SER-1868; SER-1878; SER-1882; THR-1885; SER-1899; SER-1913;
RP   SER-1920; SER-1927 AND SER-1934, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [45]
RP   INTERACTION WITH SETX.
RX   PubMed=23149945; DOI=10.1128/MCB.01195-12;
RA   Yuce O., West S.C.;
RT   "Senataxin, defective in the neurodegenerative disorder ataxia with
RT   oculomotor apraxia 2, lies at the interface of transcription and the
RT   DNA damage response.";
RL   Mol. Cell. Biol. 33:406-417(2013).
RN   [46]
RP   INTERACTION WITH PIH1D1.
RX   PubMed=24656813; DOI=10.1016/j.celrep.2014.03.013;
RA   Horejsi Z., Stach L., Flower T.G., Joshi D., Flynn H., Skehel J.M.,
RA   O'Reilly N.J., Ogrodowicz R.W., Smerdon S.J., Boulton S.J.;
RT   "Phosphorylation-dependent PIH1D1 interactions define substrate
RT   specificity of the R2TP cochaperone complex.";
RL   Cell Rep. 7:19-26(2014).
RN   [47]
RP   ACETYLATION.
RX   PubMed=24207025; DOI=10.1016/j.molcel.2013.10.009;
RA   Schroeder S., Herker E., Itzen F., He D., Thomas S., Gilchrist D.A.,
RA   Kaehlcke K., Cho S., Pollard K.S., Capra J.A., Schnoelzer M.,
RA   Cole P.A., Geyer M., Bruneau B.G., Adelman K., Ott M.;
RT   "Acetylation of RNA polymerase II regulates growth-factor-induced gene
RT   transcription in mammalian cells.";
RL   Mol. Cell 52:314-324(2013).
RN   [48]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-1874; SER-1906; TYR-1909
RP   AND TYR-1923, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [49]
RP   METHYLATION, AND ACETYLATION.
RX   PubMed=26687004; DOI=10.7554/eLife.11215;
RA   Dias J.D., Rito T., Torlai Triglia E., Kukalev A., Ferrai C.,
RA   Chotalia M., Brookes E., Kimura H., Pombo A.;
RT   "Methylation of RNA polymerase II non-consensus Lysine residues marks
RT   early transcription in mammalian cells.";
RL   Elife 4:0-0(2015).
RN   [50]
RP   INTERACTION WITH TDRD3; PRMT5; SETX; SMN1 AND XRN2, METHYLATION AT
RP   ARG-1603 AND ARG-1810, AND MUTAGENESIS OF ARG-1810.
RX   PubMed=26700805; DOI=10.1038/nature16469;
RA   Yanling Zhao D., Gish G., Braunschweig U., Li Y., Ni Z.,
RA   Schmitges F.W., Zhong G., Liu K., Li W., Moffat J., Vedadi M., Min J.,
RA   Pawson T.J., Blencowe B.J., Greenblatt J.F.;
RT   "SMN and symmetric arginine dimethylation of RNA polymerase II C-
RT   terminal domain control termination.";
RL   Nature 529:48-53(2016).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 1796-1803 IN COMPLEX WITH
RP   CTDSP1, AND DEPHOSPHORYLATION.
RX   PubMed=17157258; DOI=10.1016/j.molcel.2006.10.027;
RA   Zhang Y., Kim Y., Genoud N., Gao J., Kelly J.W., Pfaff S.L.,
RA   Gill G.N., Dixon J.E., Noel J.P.;
RT   "Determinants for dephosphorylation of the RNA polymerase II C-
RT   terminal domain by Scp1.";
RL   Mol. Cell 24:759-770(2006).
RN   [52]
RP   STRUCTURE BY ELECTRON MICROSCOPY IN COMPLEX WITH RECQL5, INTERACTION
RP   WITH RECQL5 AND TCEA1, SUBUNIT, AND FUNCTION.
RX   PubMed=23748380; DOI=10.1038/nsmb.2596;
RA   Kassube S.A., Jinek M., Fang J., Tsutakawa S., Nogales E.;
RT   "Structural mimicry in transcription regulation of human RNA
RT   polymerase II by the DNA helicase RECQL5.";
RL   Nat. Struct. Mol. Biol. 20:892-899(2013).
CC   -!- FUNCTION: DNA-dependent RNA polymerase catalyzes the transcription
CC       of DNA into RNA using the four ribonucleoside triphosphates as
CC       substrates. Largest and catalytic component of RNA polymerase II
CC       which synthesizes mRNA precursors and many functional non-coding
CC       RNAs. Forms the polymerase active center together with the second
CC       largest subunit. Pol II is the central component of the basal RNA
CC       polymerase II transcription machinery. It is composed of mobile
CC       elements that move relative to each other. RPB1 is part of the
CC       core element with the central large cleft, the clamp element that
CC       moves to open and close the cleft and the jaws that are thought to
CC       grab the incoming DNA template. At the start of transcription, a
CC       single-stranded DNA template strand of the promoter is positioned
CC       within the central active site cleft of Pol II. A bridging helix
CC       emanates from RPB1 and crosses the cleft near the catalytic site
CC       and is thought to promote translocation of Pol II by acting as a
CC       ratchet that moves the RNA-DNA hybrid through the active site by
CC       switching from straight to bent conformations at each step of
CC       nucleotide addition. During transcription elongation, Pol II moves
CC       on the template as the transcript elongates. Elongation is
CC       influenced by the phosphorylation status of the C-terminal domain
CC       (CTD) of Pol II largest subunit (RPB1), which serves as a platform
CC       for assembly of factors that regulate transcription initiation,
CC       elongation, termination and mRNA processing. Acts as an RNA-
CC       dependent RNA polymerase when associated with small delta antigen
CC       of Hepatitis delta virus, acting both as a replicate and
CC       transcriptase for the viral RNA circular genome.
CC       {ECO:0000269|PubMed:18032511, ECO:0000269|PubMed:20231364,
CC       ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:9852112}.
CC   -!- CATALYTIC ACTIVITY: Nucleoside triphosphate + RNA(n) = diphosphate
CC       + RNA(n+1).
CC   -!- SUBUNIT: Component of the RNA polymerase II (Pol II) complex
CC       consisting of 12 subunits. Component of a complex which is at
CC       least composed of HTATSF1/Tat-SF1, the P-TEFb complex components
CC       CDK9 and CCNT1, RNA polymerase II, SUPT5H, and NCL/nucleolin. The
CC       large PER complex involved in the repression of transcriptional
CC       termination is composed of at least PER2, CDK9, DDX5, DHX9, NCBP1
CC       and POLR2A (active). Interacts (via the C-terminal domain (CTD))
CC       with U2AF2; recruits PRPF19 and the Prp19 complex to the pre-mRNA
CC       and may couple transcription to pre-mRNA splicing. Interacts (via
CC       the C-terminal domain (CTD)) with SMN1/SMN2; recruits SMN1/SMN2 to
CC       RNA Pol II elongation complexes. Interacts via the phosphorylated
CC       C-terminal domain with WDR82 and with SETD1A and SETD1B only in
CC       the presence of WDR82. When phosphorylated at 'Ser-5', interacts
CC       with MEN1; the unphosphorylated form, or phosphorylated at 'Ser-2'
CC       does not interact. When phosphorylated at 'Ser-2', interacts with
CC       SUPT6H (via SH2 domain). Interacts with RECQL5 and TCEA1; binding
CC       of RECQL5 prevents TCEA1 binding. The phosphorylated C-terminal
CC       domain interacts with FNBP3 and SYNCRIP. Interacts with ATF7IP.
CC       Interacts with DDX5. Interacts with WWP2. Interacts with SETX.
CC       Interacts (phosphorylated) with PIH1D1. Interacts (via the C-
CC       terminal domain (CTD)) with TDRD3. Interacts with PRMT5. Interacts
CC       with XRN2. Interacts with SAFB/SAFB1. Interacts with CCNL1.
CC       Interacts with CCNL2, MYO1C, PAF1 and SFRS19. Interacts (via C-
CC       terminus) with CMTR1, CTDSP1 and SCAF8. Interacts (via the C-
CC       terminal domain (CTD)) with CCNT2 (PubMed:15563843).
CC       {ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:10393184,
CC       ECO:0000269|PubMed:10454543, ECO:0000269|PubMed:12376575,
CC       ECO:0000269|PubMed:12381297, ECO:0000269|PubMed:12527917,
CC       ECO:0000269|PubMed:14684736, ECO:0000269|PubMed:14992727,
CC       ECO:0000269|PubMed:15563843, ECO:0000269|PubMed:15992770,
CC       ECO:0000269|PubMed:16118227, ECO:0000269|PubMed:16314571,
CC       ECO:0000269|PubMed:16491129, ECO:0000269|PubMed:17157258,
CC       ECO:0000269|PubMed:17234882, ECO:0000269|PubMed:17998332,
CC       ECO:0000269|PubMed:18533109, ECO:0000269|PubMed:18550522,
CC       ECO:0000269|PubMed:19106100, ECO:0000269|PubMed:20231364,
CC       ECO:0000269|PubMed:21536736, ECO:0000269|PubMed:23149945,
CC       ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24656813,
CC       ECO:0000269|PubMed:26700805, ECO:0000269|PubMed:9671816,
CC       ECO:0000269|PubMed:9852112}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus
CC       1 protein ICP22; this interaction causes loss of CTD 'Ser-2'
CC       phosphorylation from pol II engaged in transcription
CC       (PubMed:23029222). {ECO:0000269|PubMed:23029222}.
CC   -!- INTERACTION:
CC       Q6P1J9:CDC73; NbExp=5; IntAct=EBI-295301, EBI-930143;
CC       P17844:DDX5; NbExp=3; IntAct=EBI-295301, EBI-351962;
CC       L8B1Q7:ORF6 (xeno); NbExp=3; IntAct=EBI-295301, EBI-11712334;
CC       Q67020:PA (xeno); NbExp=2; IntAct=EBI-295301, EBI-11514477;
CC       Q8N7H5:PAF1; NbExp=5; IntAct=EBI-295301, EBI-2607770;
CC       Q9NQG5:RPRD1B; NbExp=5; IntAct=EBI-295301, EBI-747925;
CC       Q96H20:SNF8; NbExp=2; IntAct=EBI-295301, EBI-747719;
CC       O00267:SUPT5H; NbExp=4; IntAct=EBI-295301, EBI-710464;
CC       Q9HCS7:XAB2; NbExp=2; IntAct=EBI-295301, EBI-295232;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:9852112}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P24928-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P24928-2; Sequence=VSP_056184, VSP_056185;
CC         Note=No experimental confirmation available.;
CC   -!- DOMAIN: The C-terminal domain (CTD) serves as a platform for
CC       assembly of factors that regulate transcription initiation,
CC       elongation, termination and mRNA processing.
CC       {ECO:0000303|PubMed:22137580}.
CC   -!- PTM: The tandem heptapeptide repeats in the C-terminal domain
CC       (CTD) can be highly phosphorylated. The phosphorylation activates
CC       Pol II. Phosphorylation occurs mainly at residues 'Ser-2' and
CC       'Ser-5' of the heptapeptide repeat and is mediated, at least, by
CC       CDK7 and CDK9. CDK7 phosphorylation of POLR2A associated with DNA
CC       promotes transcription initiation by triggering dissociation from
CC       DNA. Phosphorylation also takes place at 'Ser-7' of the
CC       heptapeptide repeat, which is required for efficient transcription
CC       of snRNA genes and processing of the transcripts. The
CC       phosphorylation state is believed to result from the balanced
CC       action of site-specific CTD kinases and phosphatases, and a 'CTD
CC       code' that specifies the position of Pol II within the
CC       transcription cycle has been proposed. Dephosphorylated by the
CC       protein phosphatase CTDSP1. {ECO:0000269|PubMed:17157258,
CC       ECO:0000269|PubMed:17234882, ECO:0000269|PubMed:19136461,
CC       ECO:0000269|PubMed:19450536, ECO:0000269|PubMed:19667075,
CC       ECO:0000269|PubMed:21127351, ECO:0000269|PubMed:22137580}.
CC   -!- PTM: Among tandem heptapeptide repeats of the C-terminal domain
CC       (CTD) some do not match the Y-S-P-T-S-P-S consensus, the seventh
CC       serine residue 'Ser-7' being replaced by a lysine. 'Lys-7' in
CC       these non-consensus heptapeptide repeats can be alternatively
CC       acetylated, methylated and dimethylated. EP300 is one of the
CC       enzyme able to acetylate 'Lys-7'. Acetylation at 'Lys-7' of non-
CC       consensus heptapeptide repeats is associated with 'Ser-2'
CC       phosphorylation and active transcription. It may regulate
CC       initiation or early elongation steps of transcription specially
CC       for inducible genes. {ECO:0000269|PubMed:24207025,
CC       ECO:0000269|PubMed:26687004}.
CC   -!- PTM: Methylated at Arg-1810 prior to transcription initiation when
CC       the CTD is hypophosphorylated, phosphorylation at Ser-1805 and
CC       Ser-1808 preventing this methylation. Symmetrically or
CC       asymmetrically dimethylated at Arg-1810 by PRMT5 and CARM1
CC       respectively. Symmetric or asymmetric dimethylation modulates
CC       interactions with CTD-binding proteins like SMN1/SMN2 and TDRD3.
CC       SMN1/SMN2 interacts preferentially with the symmetrically
CC       dimethylated form while TDRD3 interacts with the asymmetric form.
CC       Through the recruitment of SMN1/SMN2, symmetric dimethylation is
CC       required for resolving RNA-DNA hybrids created by RNA polymerase
CC       II, that form R-loop in transcription terminal regions, an
CC       important step in proper transcription termination. CTD
CC       dimethylation may also facilitate the expression of select RNAs.
CC       Among tandem heptapeptide repeats of the C-terminal domain (CTD)
CC       some do not match the Y-S-P-T-S-P-S consensus, the seventh serine
CC       residue 'Ser-7' being replaced by a lysine. 'Lys-7' in these non-
CC       consensus heptapeptide repeats can be alternatively acetylated,
CC       methylated and dimethylated. Methylation occurs in the earliest
CC       transcription stages and precedes or is concomitant to 'Ser-5' and
CC       'Ser-7' phosphorylation. {ECO:0000269|PubMed:26687004,
CC       ECO:0000269|PubMed:26700805}.
CC   -!- PTM: Ubiquitinated by WWP2 leading to proteasomal degradation (By
CC       similarity). Following UV treatment, the elongating form of RNA
CC       polymerase II (RNA pol IIo) is ubiquitinated UV damage sites
CC       without leading to degradation: ubiquitination is facilitated by
CC       KIAA1530/UVSSA and promotes RNA pol IIo backtracking to allow
CC       access to the nucleotide excision repair machinery. {ECO:0000250,
CC       ECO:0000269|PubMed:22466610}.
CC   -!- MISCELLANEOUS: The binding of ribonucleoside triphosphate to the
CC       RNA polymerase II transcribing complex probably involves a two-
CC       step mechanism. The initial binding seems to occur at the entry
CC       (E) site and involves a magnesium ion temporarily coordinated by
CC       three conserved aspartate residues of the two largest RNA Pol II
CC       subunits. The ribonucleoside triphosphate is transferred by a
CC       rotation to the nucleotide addition (A) site for pairing with the
CC       template DNA. The catalytic A site involves three conserved
CC       aspartate residues of the RNA Pol II largest subunit which
CC       permanently coordinate a second magnesium ion.
CC   -!- SIMILARITY: Belongs to the RNA polymerase beta' chain family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X63564; CAA45125.1; -; mRNA.
DR   EMBL; X74874; CAA52862.1; -; Genomic_DNA.
DR   EMBL; X74873; CAA52862.1; JOINED; Genomic_DNA.
DR   EMBL; X74872; CAA52862.1; JOINED; Genomic_DNA.
DR   EMBL; X74871; CAA52862.1; JOINED; Genomic_DNA.
DR   EMBL; X74870; CAA52862.1; JOINED; Genomic_DNA.
DR   EMBL; AC113189; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW90181.1; -; Genomic_DNA.
DR   EMBL; BC067295; AAH67295.1; -; mRNA.
DR   EMBL; BC137231; AAI37232.1; -; mRNA.
DR   PIR; I38186; I38186.
DR   PIR; S21054; S21054.
DR   RefSeq; NP_000928.1; NM_000937.4.
DR   UniGene; Hs.270017; -.
DR   PDB; 2GHQ; X-ray; 2.05 A; C/D=1795-1803.
DR   PDB; 2GHT; X-ray; 1.80 A; C/D=1796-1803.
DR   PDB; 2LTO; NMR; -; B=1804-1816.
DR   PDB; 3D9K; X-ray; 2.20 A; Y/Z=1790-1803.
DR   PDB; 3D9L; X-ray; 2.20 A; Y/Z=1790-1803.
DR   PDB; 3D9M; X-ray; 1.75 A; Y/Z=1790-1803.
DR   PDB; 3D9N; X-ray; 1.60 A; Y/Z=1790-1803.
DR   PDB; 3D9O; X-ray; 2.00 A; Z=1790-1803.
DR   PDB; 3D9P; X-ray; 2.10 A; Y/Z=1790-1803.
DR   PDB; 4JXT; X-ray; 1.90 A; B=1787-1805.
DR   PDB; 5IY6; EM; 7.20 A; A=1-1970.
DR   PDB; 5IY7; EM; 8.60 A; A=1-1970.
DR   PDB; 5IY8; EM; 7.90 A; A=1-1970.
DR   PDB; 5IY9; EM; 6.30 A; A=1-1970.
DR   PDB; 5IYA; EM; 5.40 A; A=1-1970.
DR   PDB; 5IYB; EM; 3.90 A; A=1-1970.
DR   PDB; 5IYC; EM; 3.90 A; A=1-1970.
DR   PDB; 5IYD; EM; 3.90 A; A=1-1970.
DR   PDB; 5M3H; X-ray; 2.50 A; X/Y=1713-1740.
DR   PDB; 5M3J; X-ray; 3.50 A; X=1713-1740.
DR   PDBsum; 2GHQ; -.
DR   PDBsum; 2GHT; -.
DR   PDBsum; 2LTO; -.
DR   PDBsum; 3D9K; -.
DR   PDBsum; 3D9L; -.
DR   PDBsum; 3D9M; -.
DR   PDBsum; 3D9N; -.
DR   PDBsum; 3D9O; -.
DR   PDBsum; 3D9P; -.
DR   PDBsum; 4JXT; -.
DR   PDBsum; 5IY6; -.
DR   PDBsum; 5IY7; -.
DR   PDBsum; 5IY8; -.
DR   PDBsum; 5IY9; -.
DR   PDBsum; 5IYA; -.
DR   PDBsum; 5IYB; -.
DR   PDBsum; 5IYC; -.
DR   PDBsum; 5IYD; -.
DR   PDBsum; 5M3H; -.
DR   PDBsum; 5M3J; -.
DR   ProteinModelPortal; P24928; -.
DR   SMR; P24928; -.
DR   BioGrid; 111426; 277.
DR   DIP; DIP-29011N; -.
DR   IntAct; P24928; 67.
DR   MINT; MINT-156582; -.
DR   STRING; 9606.ENSP00000314949; -.
DR   BindingDB; P24928; -.
DR   ChEMBL; CHEMBL1641353; -.
DR   iPTMnet; P24928; -.
DR   PhosphoSitePlus; P24928; -.
DR   BioMuta; POLR2A; -.
DR   DMDM; 281185484; -.
DR   EPD; P24928; -.
DR   MaxQB; P24928; -.
DR   PaxDb; P24928; -.
DR   PeptideAtlas; P24928; -.
DR   PRIDE; P24928; -.
DR   Ensembl; ENST00000572844; ENSP00000461879; ENSG00000181222. [P24928-2]
DR   GeneID; 5430; -.
DR   KEGG; hsa:5430; -.
DR   UCSC; uc002ghe.4; human. [P24928-1]
DR   CTD; 5430; -.
DR   DisGeNET; 5430; -.
DR   GeneCards; POLR2A; -.
DR   H-InvDB; HIX0173727; -.
DR   HGNC; HGNC:9187; POLR2A.
DR   HPA; CAB012226; -.
DR   HPA; CAB016388; -.
DR   HPA; CAB022311; -.
DR   HPA; HPA021563; -.
DR   HPA; HPA053012; -.
DR   MIM; 180660; gene+phenotype.
DR   neXtProt; NX_P24928; -.
DR   OpenTargets; ENSG00000181222; -.
DR   PharmGKB; PA33507; -.
DR   eggNOG; KOG0260; Eukaryota.
DR   eggNOG; COG0086; LUCA.
DR   GeneTree; ENSGT00870000136522; -.
DR   HOGENOM; HOG000222975; -.
DR   HOVERGEN; HBG004339; -.
DR   InParanoid; P24928; -.
DR   KO; K03006; -.
DR   PhylomeDB; P24928; -.
DR   TreeFam; TF103036; -.
DR   Reactome; R-HSA-112382; Formation of RNA Pol II elongation complex.
DR   Reactome; R-HSA-112387; Elongation arrest and recovery.
DR   Reactome; R-HSA-113418; Formation of the Early Elongation Complex.
DR   Reactome; R-HSA-167152; Formation of HIV elongation complex in the absence of HIV Tat.
DR   Reactome; R-HSA-167158; Formation of the HIV-1 Early Elongation Complex.
DR   Reactome; R-HSA-167160; RNA Pol II CTD phosphorylation and interaction with CE during HIV infection.
DR   Reactome; R-HSA-167161; HIV Transcription Initiation.
DR   Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape.
DR   Reactome; R-HSA-167172; Transcription of the HIV genome.
DR   Reactome; R-HSA-167200; Formation of HIV-1 elongation complex containing HIV-1 Tat.
DR   Reactome; R-HSA-167238; Pausing and recovery of Tat-mediated HIV elongation.
DR   Reactome; R-HSA-167242; Abortive elongation of HIV-1 transcript in the absence of Tat.
DR   Reactome; R-HSA-167243; Tat-mediated HIV elongation arrest and recovery.
DR   Reactome; R-HSA-167246; Tat-mediated elongation of the HIV-1 transcript.
DR   Reactome; R-HSA-167287; HIV elongation arrest and recovery.
DR   Reactome; R-HSA-167290; Pausing and recovery of HIV elongation.
DR   Reactome; R-HSA-168325; Viral Messenger RNA Synthesis.
DR   Reactome; R-HSA-203927; MicroRNA (miRNA) biogenesis.
DR   Reactome; R-HSA-452723; Transcriptional regulation of pluripotent stem cells.
DR   Reactome; R-HSA-5578749; Transcriptional regulation by small RNAs.
DR   Reactome; R-HSA-5601884; PIWI-interacting RNA (piRNA) biogenesis.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6781823; Formation of TC-NER Pre-Incision Complex.
DR   Reactome; R-HSA-6781827; Transcription-Coupled Nucleotide Excision Repair (TC-NER).
DR   Reactome; R-HSA-6782135; Dual incision in TC-NER.
DR   Reactome; R-HSA-6782210; Gap-filling DNA repair synthesis and ligation in TC-NER.
DR   Reactome; R-HSA-6796648; TP53 Regulates Transcription of DNA Repair Genes.
DR   Reactome; R-HSA-6803529; FGFR2 alternative splicing.
DR   Reactome; R-HSA-6807505; RNA polymerase II transcribes snRNA genes.
DR   Reactome; R-HSA-72086; mRNA Capping.
DR   Reactome; R-HSA-72163; mRNA Splicing - Major Pathway.
DR   Reactome; R-HSA-72165; mRNA Splicing - Minor Pathway.
DR   Reactome; R-HSA-72203; Processing of Capped Intron-Containing Pre-mRNA.
DR   Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape.
DR   Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening.
DR   Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation.
DR   Reactome; R-HSA-75955; RNA Polymerase II Transcription Elongation.
DR   Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance.
DR   Reactome; R-HSA-77075; RNA Pol II CTD phosphorylation and interaction with CE.
DR   Reactome; R-HSA-8851708; Signaling by FGFR2 IIIa TM.
DR   SIGNOR; P24928; -.
DR   ChiTaRS; POLR2A; human.
DR   EvolutionaryTrace; P24928; -.
DR   GeneWiki; POLR2A; -.
DR   GenomeRNAi; 5430; -.
DR   PRO; PR:P24928; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000181222; -.
DR   CleanEx; HS_POLR2A; -.
DR   ExpressionAtlas; P24928; baseline and differential.
DR   Genevisible; P24928; HS.
DR   GO; GO:0005665; C:DNA-directed RNA polymerase II, core complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0003899; F:DNA-directed 5'-3' RNA polymerase activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0003968; F:RNA-directed 5'-3' RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0006370; P:7-methylguanosine mRNA capping; TAS:Reactome.
DR   GO; GO:0006353; P:DNA-templated transcription, termination; IMP:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0010467; P:gene expression; TAS:Reactome.
DR   GO; GO:0031047; P:gene silencing by RNA; TAS:Reactome.
DR   GO; GO:0000398; P:mRNA splicing, via spliceosome; TAS:Reactome.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; IDA:UniProtKB.
DR   GO; GO:0050434; P:positive regulation of viral transcription; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; NAS:UniProtKB.
DR   GO; GO:0042795; P:snRNA transcription from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0035019; P:somatic stem cell population maintenance; TAS:Reactome.
DR   GO; GO:0006368; P:transcription elongation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006366; P:transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0006367; P:transcription initiation from RNA polymerase II promoter; TAS:Reactome.
DR   GO; GO:0006283; P:transcription-coupled nucleotide-excision repair; TAS:Reactome.
DR   InterPro; IPR000722; RNA_pol_asu.
DR   InterPro; IPR000684; RNA_pol_II_repeat_euk.
DR   InterPro; IPR006592; RNA_pol_N.
DR   InterPro; IPR007080; RNA_pol_Rpb1_1.
DR   InterPro; IPR007066; RNA_pol_Rpb1_3.
DR   InterPro; IPR007083; RNA_pol_Rpb1_4.
DR   InterPro; IPR007081; RNA_pol_Rpb1_5.
DR   InterPro; IPR007075; RNA_pol_Rpb1_6.
DR   InterPro; IPR007073; RNA_pol_Rpb1_7.
DR   Pfam; PF04997; RNA_pol_Rpb1_1; 1.
DR   Pfam; PF00623; RNA_pol_Rpb1_2; 1.
DR   Pfam; PF04983; RNA_pol_Rpb1_3; 1.
DR   Pfam; PF05000; RNA_pol_Rpb1_4; 1.
DR   Pfam; PF04998; RNA_pol_Rpb1_5; 1.
DR   Pfam; PF04992; RNA_pol_Rpb1_6; 1.
DR   Pfam; PF04990; RNA_pol_Rpb1_7; 1.
DR   Pfam; PF05001; RNA_pol_Rpb1_R; 40.
DR   SMART; SM00663; RPOLA_N; 1.
DR   PROSITE; PS00115; RNA_POL_II_REPEAT; 42.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   DNA-binding; DNA-directed RNA polymerase; Magnesium; Metal-binding;
KW   Methylation; Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; RNA-directed RNA polymerase;
KW   Transcription; Transferase; Ubl conjugation; Zinc.
FT   CHAIN         1   1970       DNA-directed RNA polymerase II subunit
FT                                RPB1.
FT                                /FTId=PRO_0000073940.
FT   REPEAT     1593   1599       1.
FT   REPEAT     1600   1606       2; approximate.
FT   REPEAT     1608   1614       3.
FT   REPEAT     1615   1621       4.
FT   REPEAT     1622   1628       5.
FT   REPEAT     1629   1635       6.
FT   REPEAT     1636   1642       7.
FT   REPEAT     1643   1649       8.
FT   REPEAT     1650   1656       9.
FT   REPEAT     1657   1663       10.
FT   REPEAT     1664   1670       11.
FT   REPEAT     1671   1677       12.
FT   REPEAT     1678   1684       13.
FT   REPEAT     1685   1691       14.
FT   REPEAT     1692   1698       15.
FT   REPEAT     1699   1705       16.
FT   REPEAT     1706   1712       17.
FT   REPEAT     1713   1719       18.
FT   REPEAT     1720   1726       19.
FT   REPEAT     1727   1733       20.
FT   REPEAT     1734   1740       21.
FT   REPEAT     1741   1747       22.
FT   REPEAT     1748   1754       23.
FT   REPEAT     1755   1761       24.
FT   REPEAT     1762   1768       25.
FT   REPEAT     1769   1775       26.
FT   REPEAT     1776   1782       27.
FT   REPEAT     1783   1789       28.
FT   REPEAT     1790   1796       29.
FT   REPEAT     1797   1803       30.
FT   REPEAT     1804   1810       31.
FT   REPEAT     1811   1817       32.
FT   REPEAT     1818   1824       33.
FT   REPEAT     1825   1831       34.
FT   REPEAT     1832   1838       35.
FT   REPEAT     1839   1845       36.
FT   REPEAT     1846   1852       37.
FT   REPEAT     1853   1859       38.
FT   REPEAT     1860   1866       39.
FT   REPEAT     1867   1873       40.
FT   REPEAT     1874   1880       41.
FT   REPEAT     1881   1887       42.
FT   REPEAT     1888   1894       43.
FT   REPEAT     1895   1901       44.
FT   REPEAT     1902   1908       45.
FT   REPEAT     1909   1915       46.
FT   REPEAT     1916   1922       47.
FT   REPEAT     1923   1929       48.
FT   REPEAT     1930   1936       49.
FT   REPEAT     1940   1946       50.
FT   REPEAT     1947   1953       51; approximate.
FT   REPEAT     1954   1960       52; approximate.
FT   REGION      833    845       Bridging helix.
FT   REGION     1593   1960       C-terminal domain (CTD); 52 X 7 AA
FT                                approximate tandem repeats of Y-[ST]-P-
FT                                [STQ]-[ST]-P-[SRTEVKGN].
FT   METAL        71     71       Zinc 1. {ECO:0000250}.
FT   METAL        74     74       Zinc 1. {ECO:0000250}.
FT   METAL        81     81       Zinc 1. {ECO:0000250}.
FT   METAL        84     84       Zinc 1. {ECO:0000250}.
FT   METAL       111    111       Zinc 2. {ECO:0000250}.
FT   METAL       114    114       Zinc 2. {ECO:0000250}.
FT   METAL       154    154       Zinc 2. {ECO:0000250}.
FT   METAL       184    184       Zinc 2. {ECO:0000250}.
FT   METAL       495    495       Magnesium 1; catalytic. {ECO:0000250}.
FT   METAL       495    495       Magnesium 2; shared with RPB2.
FT                                {ECO:0000250}.
FT   METAL       497    497       Magnesium 1; catalytic. {ECO:0000250}.
FT   METAL       497    497       Magnesium 2; shared with RPB2.
FT                                {ECO:0000250}.
FT   METAL       499    499       Magnesium 1; catalytic. {ECO:0000250}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      27     27       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     217    217       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1603   1603       Omega-N-methylated arginine; by CARM1; in
FT                                vitro. {ECO:0000269|PubMed:26700805}.
FT   MOD_RES    1810   1810       Asymmetric dimethylarginine; alternate;
FT                                by CARM1. {ECO:0000269|PubMed:21454787,
FT                                ECO:0000269|PubMed:26700805}.
FT   MOD_RES    1810   1810       Symmetric dimethylarginine; alternate; by
FT                                PRMT5. {ECO:0000269|PubMed:26700805}.
FT   MOD_RES    1843   1843       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1847   1847       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08775}.
FT   MOD_RES    1849   1849       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1850   1850       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1854   1854       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1857   1857       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08775}.
FT   MOD_RES    1864   1864       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1868   1868       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1874   1874       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1878   1878       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1882   1882       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1885   1885       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1894   1894       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08775}.
FT   MOD_RES    1896   1896       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    1899   1899       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1906   1906       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1909   1909       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1912   1912       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08775}.
FT   MOD_RES    1913   1913       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1917   1917       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1920   1920       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1923   1923       Phosphotyrosine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1926   1926       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P08775}.
FT   MOD_RES    1927   1927       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1931   1931       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1934   1934       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ     558    566       GEVMNLLMF -> VCGPNGNLA (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056184.
FT   VAR_SEQ     567   1970       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056185.
FT   VARIANT     292    292       R -> C (in dbSNP:rs2229198).
FT                                /FTId=VAR_051872.
FT   MUTAGEN    1810   1810       R->A: Misexpression of a variety of small
FT                                nuclear RNAs and small nucleolar RNAs.
FT                                Loss of interaction with TDRD3 and
FT                                SMN1/SMN2. {ECO:0000269|PubMed:21454787,
FT                                ECO:0000269|PubMed:26700805}.
FT   CONFLICT   1067   1067       W -> L (in Ref. 2; CAA52862).
FT                                {ECO:0000305}.
FT   CONFLICT   1449   1449       D -> Y (in Ref. 2; CAA52862).
FT                                {ECO:0000305}.
FT   CONFLICT   1835   1835       A -> T (in Ref. 1; CAA45125 and 2;
FT                                CAA52862). {ECO:0000305}.
FT   STRAND     1722   1724       {ECO:0000244|PDB:5M3H}.
FT   STRAND     1808   1811       {ECO:0000244|PDB:2LTO}.
SQ   SEQUENCE   1970 AA;  217176 MW;  28D6FD25693A6472 CRC64;
     MHGGGPPSGD SACPLRTIKR VQFGVLSPDE LKRMSVTEGG IKYPETTEGG RPKLGGLMDP
     RQGVIERTGR CQTCAGNMTE CPGHFGHIEL AKPVFHVGFL VKTMKVLRCV CFFCSKLLVD
     SNNPKIKDIL AKSKGQPKKR LTHVYDLCKG KNICEGGEEM DNKFGVEQPE GDEDLTKEKG
     HGGCGRYQPR IRRSGLELYA EWKHVNEDSQ EKKILLSPER VHEIFKRISD EECFVLGMEP
     RYARPEWMIV TVLPVPPLSV RPAVVMQGSA RNQDDLTHKL ADIVKINNQL RRNEQNGAAA
     HVIAEDVKLL QFHVATMVDN ELPGLPRAMQ KSGRPLKSLK QRLKGKEGRV RGNLMGKRVD
     FSARTVITPD PNLSIDQVGV PRSIAANMTF AEIVTPFNID RLQELVRRGN SQYPGAKYII
     RDNGDRIDLR FHPKPSDLHL QTGYKVERHM CDGDIVIFNR QPTLHKMSMM GHRVRILPWS
     TFRLNLSVTT PYNADFDGDE MNLHLPQSLE TRAEIQELAM VPRMIVTPQS NRPVMGIVQD
     TLTAVRKFTK RDVFLERGEV MNLLMFLSTW DGKVPQPAIL KPRPLWTGKQ IFSLIIPGHI
     NCIRTHSTHP DDEDSGPYKH ISPGDTKVVV ENGELIMGIL CKKSLGTSAG SLVHISYLEM
     GHDITRLFYS NIQTVINNWL LIEGHTIGIG DSIADSKTYQ DIQNTIKKAK QDVIEVIEKA
     HNNELEPTPG NTLRQTFENQ VNRILNDARD KTGSSAQKSL SEYNNFKSMV VSGAKGSKIN
     ISQVIAVVGQ QNVEGKRIPF GFKHRTLPHF IKDDYGPESR GFVENSYLAG LTPTEFFFHA
     MGGREGLIDT AVKTAETGYI QRRLIKSMES VMVKYDATVR NSINQVVQLR YGEDGLAGES
     VEFQNLATLK PSNKAFEKKF RFDYTNERAL RRTLQEDLVK DVLSNAHIQN ELEREFERMR
     EDREVLRVIF PTGDSKVVLP CNLLRMIWNA QKIFHINPRL PSDLHPIKVV EGVKELSKKL
     VIVNGDDPLS RQAQENATLL FNIHLRSTLC SRRMAEEFRL SGEAFDWLLG EIESKFNQAI
     AHPGEMVGAL AAQSLGEPAT QMTLNTFHYA GVSAKNVTLG VPRLKELINI SKKPKTPSLT
     VFLLGQSARD AERAKDILCR LEHTTLRKVT ANTAIYYDPN PQSTVVAEDQ EWVNVYYEMP
     DFDVARISPW LLRVELDRKH MTDRKLTMEQ IAEKINAGFG DDLNCIFNDD NAEKLVLRIR
     IMNSDENKMQ EEEEVVDKMD DDVFLRCIES NMLTDMTLQG IEQISKVYMH LPQTDNKKKI
     IITEDGEFKA LQEWILETDG VSLMRVLSEK DVDPVRTTSN DIVEIFTVLG IEAVRKALER
     ELYHVISFDG SYVNYRHLAL LCDTMTCRGH LMAITRHGVN RQDTGPLMKC SFEETVDVLM
     EAAAHGESDP MKGVSENIML GQLAPAGTGC FDLLLDAEKC KYGMEIPTNI PGLGAAGPTG
     MFFGSAPSPM GGISPAMTPW NQGATPAYGA WSPSVGSGMT PGAAGFSPSA ASDASGFSPG
     YSPAWSPTPG SPGSPGPSSP YIPSPGGAMS PSYSPTSPAY EPRSPGGYTP QSPSYSPTSP
     SYSPTSPSYS PTSPNYSPTS PSYSPTSPSY SPTSPSYSPT SPSYSPTSPS YSPTSPSYSP
     TSPSYSPTSP SYSPTSPSYS PTSPSYSPTS PSYSPTSPSY SPTSPSYSPT SPSYSPTSPS
     YSPTSPNYSP TSPNYTPTSP SYSPTSPSYS PTSPNYTPTS PNYSPTSPSY SPTSPSYSPT
     SPSYSPSSPR YTPQSPTYTP SSPSYSPSSP SYSPASPKYT PTSPSYSPSS PEYTPTSPKY
     SPTSPKYSPT SPKYSPTSPT YSPTTPKYSP TSPTYSPTSP VYTPTSPKYS PTSPTYSPTS
     PKYSPTSPTY SPTSPKGSTY SPTSPGYSPT SPTYSLTSPA ISPDDSDEEN
//
